November was a rough month to be an investor in pharma giant Eli Lilly (NYSE: LLY). Shares dropped by more than 8% during the period, erasing more than $6 billion from the company’s market cap, according to data fromĀ S&P Global Market Intelligence.
November was a rough month to be an investor in pharma giant Eli Lilly (NYSE: LLY). Shares dropped by more than 8% during the period, erasing more than $6 billion from the company’s market cap, according to data fromĀ S&P Global Market Intelligence.